X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs VENUS REMEDIES - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA VENUS REMEDIES ASTRAZENECA PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 155.7 -4.1 - View Chart
P/BV x 24.2 0.2 15,931.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
VENUS REMEDIES
Mar-18
ASTRAZENECA PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,285126 1,020.7%   
Low Rs63461 1,037.6%   
Sales per share (Unadj.) Rs189.6301.8 62.8%  
Earnings per share (Unadj.) Rs-0.2-24.9 0.8%  
Cash flow per share (Unadj.) Rs3.82.5 151.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.6293.3 23.4%  
Shares outstanding (eoy) m25.0012.34 202.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.10.3 1,633.5%   
Avg P/E ratio x-4,712.7-3.8 125,353.7%  
P/CF ratio (eoy) x249.636.7 679.2%  
Price / Book Value ratio x14.00.3 4,384.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,9881,154 2,079.0%   
No. of employees `0001.60.9 168.5%   
Total wages/salary Rs m1,605393 408.2%   
Avg. sales/employee Rs Th3,040.24,026.1 75.5%   
Avg. wages/employee Rs Th1,029.2425.0 242.2%   
Avg. net profit/employee Rs Th-3.3-331.8 1.0%   
INCOME DATA
Net Sales Rs m4,7403,724 127.3%  
Other income Rs m9223 409.3%   
Total revenues Rs m4,8323,747 129.0%   
Gross profit Rs m-130395 -32.9%  
Depreciation Rs m101338 29.9%   
Interest Rs m0354 0.0%   
Profit before tax Rs m-139-275 50.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m532 16.1%   
Profit after tax Rs m-5-307 1.7%  
Gross profit margin %-2.710.6 -25.8%  
Effective tax rate %-3.7-11.5 31.9%   
Net profit margin %-0.1-8.2 1.3%  
BALANCE SHEET DATA
Current assets Rs m2,7262,638 103.4%   
Current liabilities Rs m2,4352,305 105.7%   
Net working cap to sales %6.18.9 68.8%  
Current ratio x1.11.1 97.8%  
Inventory Days Days74135 54.5%  
Debtors Days Days4146 88.0%  
Net fixed assets Rs m1,0354,871 21.3%   
Share capital Rs m50123 40.5%   
"Free" reserves Rs m9423,496 27.0%   
Net worth Rs m1,7163,619 47.4%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m4,1567,509 55.4%  
Interest coverage xNM0.2-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.10.5 229.9%   
Return on assets %-0.10.6 -19.4%  
Return on equity %-0.3-8.5 3.5%  
Return on capital %01.6 0.0%  
Exports to sales %5.70-   
Imports to sales %6.513.9 46.6%   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306517 59.3%   
Fx inflow Rs m3750-   
Fx outflow Rs m470517 91.0%   
Net fx Rs m-96-517 18.5%   
CASH FLOW
From Operations Rs m-8514 -1.6%  
From Investments Rs m-146-123 118.4%  
From Financial Activity Rs m862-387 -222.7%  
Net Cashflow Rs m7094 16,869.0%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.2 166.7%  
FIIs % 15.7 0.6 2,706.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 66.4 13.7%  
Shareholders   12,856 20,121 63.9%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PLETHICO PHARMA  BIOCON LTD  J.B.CHEMICALS  ALKEM LABORATORIES  DIVIS LABORATORIES  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Nov 16, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS